Live Feeds
● TRACKER Updated 9d ago · 33 sources tracked

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

Wall Street attention has intensified around BioNTech and Moderna as both companies compete in the personalized mRNA cancer vaccine market. Moderna previously saw its shares more than double following positive Phase 3 results for its intismeran autogene melanoma vaccine. The 1,137-patient trial showed the neoantigen therapy reduced melanoma recurrence risk by roughly half, despite a subsequent 5.13 percent share price decline on August 24 due to profit-taking. Meanwhile, competitor BioNTech has faced financial headwinds, reporting a 1.35 billion euro loss for the first half of 2026 while restructuring and shifting focus toward its own cancer pipeline.

RSS Source map (33)

What changed

Financial analysts and market observers are increasingly evaluating both companies to determine the leading stock in the competitive cancer vaccine sector.

Live updates

  1. Wall Street Focuses on BioNTech and Moderna Cancer Vaccines

    Wall Street attention has intensified around BioNTech and Moderna as both companies compete in the personalized mRNA cancer vaccine market. Moderna previously saw its shares more than double following positive Phase 3 results for its intismeran autogene melanoma vaccine. The 1,137-patient trial showed the neoantigen therapy reduced melanoma recurrence risk by roughly half, despite a subsequent 5.13 percent share price decline on August 24 due to profit-taking. Meanwhile, competitor BioNTech has faced financial headwinds, reporting a 1.35 billion euro loss for the first half of 2026 while restructuring and shifting focus toward its own cancer pipeline.

    Why it matters

    The rivalry highlights a major commercial and scientific push into personalized mRNA therapies beyond infectious diseases. While Moderna leverages strong late-stage trial outcomes to capture market interest, BioNTech is actively reorganizing its leadership and pipeline to compete in the oncology sector.

    What is confirmed

    • Wall Street has recently attracted considerable attention toward both BioNTech and Moderna regarding their cancer vaccine stocks.

    What to watch next

    • Further financial performance reports from BioNTech and Moderna
    • Updates on regulatory submissions or commercialization timelines for intismeran autogene and competitor cancer pipelines
    Sources used for this update (4)
    1. www.fool.com — BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
    2. jen.jiji.com — US Open, today Alcaraz-Wu - Live
    3. jen.jiji.com — Earthquake today in Cosenza, magnitude 3.7 tremor: felt throughout the province
    4. www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
    confidence 100%

  2. Moderna mRNA Cancer Vaccine Success Contrast with BioNTech Restructuring

    Moderna shares more than doubled following positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran autogene. The trial involving 1,137 patients showed the neoantigen therapy reduced melanoma recurrence risk by roughly half. While profit-taking led to a 5.13% decline on August 24, the results position Moderna against competitor BioNTech. BioNTech is currently restructuring, naming a successor to Sahin and reporting a 1.35 billion euro loss for the first half of 2026 as it shifts its focus toward its own cancer pipeline.

    Why it matters

    The success of intismeran autogene marks the first positive Phase 3 result for a neoantigen therapy. This development occurs as mRNA technology expands from infectious diseases into oncology. The financial disparity between the two companies highlights different trajectories in the commercialization of cancer vaccines.

    What is confirmed

    • Moderna's intismeran autogene reduced melanoma recurrence risk by roughly half in a 1,137-patient Phase 3 trial.
    • Moderna shares more than doubled before declining 5.13% on August 24.
    • BioNTech reported a 1.35 billion euro loss for the first half of 2026.
    • BioNTech is restructuring and naming a successor to Sahin.

    What to watch next

    • Regulatory filing dates for intismeran autogene
    • BioNTech's progress on its own cancer pipeline
    • Further fluctuations in Moderna share price following the Phase 3 results
    Sources used for this update (15)
    1. jen.jiji.com — Samurai Jay, technical problems during the concert: "He's off-key even with autotune"
    2. jen.jiji.com — Niger, chaos in Niamey: TV broadcasts interrupted
    3. jen.jiji.com — US Open, it begins: from Paolini to Djokovic, today's matches and where to watch them for free
    4. jen.jiji.com — MotoGP, Aragon GP arrival order and World Championship standings
    5. jen.jiji.com — Italy-Spain, Schengen halt expires today. Ceuta still in crisis
    6. jen.jiji.com — US Open, Djokovic and physical problems: vomiting and inhaler on court - Video
    7. jen.jiji.com — Ranucci, the perpetrators of the attack remain in prison
    8. jen.jiji.com — Rome, Ndicka stops: injury during warm-up against Lecce
    9. jen.jiji.com — Mario Calabresi leaves Chora Media: towards candidacy for mayor of Milan
    10. jen.jiji.com — Fired at 57, a man decides to travel Europe... with 900 euros
    11. jen.jiji.com — Blue Green Economy Award 2026, the awards ceremony on September 16 in Naples
    12. finance.yahoo.com — Is BioNTech Stock a No-Brainer Buy on the Dip?
    confidence 100%

  3. Moderna Cancer Vaccine Success Prompts Industry Shifts

    Moderna's personalized mRNA cancer vaccine, intismeran autogene, has demonstrated the first positive Phase 3 results for a neoantigen therapy, reducing melanoma recurrence risk by roughly half in a 1,137-patient trial. While Moderna shares initially more than doubled before a 5.13% decline on August 24 due to profit-taking, the success creates a contrast with competitor BioNTech. BioNTech is currently restructuring, naming a successor to Sahin and reporting a 1.35 billion euro loss for the first half of 2026 while pivoting toward its own cancer pipeline.

    Why it matters

    Personalized mRNA vaccines target specific mutations in a patient's tumor to prevent cancer from returning. These results validate the clinical viability of neoantigen technology but highlight the financial volatility of the biotech sector.

    What is confirmed

    • Intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients.
    • Moderna shares fell 5.13% on August 24 after previously more than doubling.
    • BioNTech reported a 1.35 billion euro loss for the first half of 2026.

    What to watch next

    • Further research to move personalized vaccines from trials to general clinic use
    • BioNTech's updated 2026 guidance following its restructuring
    Sources used for this update (6)
    1. jen.jiji.com — Europa League, today the draw for Milan and Juventus: time, pots, and where to watch it
    2. www.ad-hoc-news.de — BioNTech's Balancing Act: A New CEO, a Costly Pivot, and a Pipeline That Must Prove Itself
    3. www.newscase.com — BioNTech’s Sympathy Surge Masks a Structural Squeeze
    4. www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
    5. jen.jiji.com — Ranucci, Milena Gabanelli: "Change in leadership? Long live Report"
    6. jen.jiji.com — Extreme heat doesn't let up in the South, fiery weekend ahead: today 6 red alerts, respite in the North
    confidence 90%

  4. Moderna Stock Volatility Follows Phase 3 Cancer Vaccine Success

    Moderna shares experienced a sharp decline of 5.13% on August 24 following a period where the stock more than doubled. This volatility follows the August 19 announcement that intismeran autogene, a personalized mRNA vaccine developed with Merck, reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. While the clinical results mark the first positive Phase 3 outcome for a personalized neoantigen mRNA cancer vaccine, investors have since engaged in profit-taking and valuation resets, with analysts keeping price targets below the recent peak.

    Why it matters

    The trial success demonstrates the potential of personalized mRNA technology to treat cancer by targeting specific neoantigens. This represents a significant milestone in oncology, though market reactions highlight a gap between clinical achievement and long-term valuation.

    What is confirmed

    • Moderna and Merck reported that intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial involving 1,137 patients.
    • Moderna shares more than doubled initially after the vaccine announcement before falling 5.13% on August 24.
    • The intismeran autogene trial is the first personalized neoantigen mRNA cancer vaccine to yield positive Phase 3 results.

    What to watch next

    • FDA regulatory filing dates for intismeran autogene
    • Updated analyst price targets following the August 24 valuation reset
    Sources used for this update (4)
    1. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
    2. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
    3. jen.jiji.com — Attack on Ranucci, tomorrow the interrogation of those arrested. The defense: "They will reiterate that they did not know Lavitola"
    4. jen.jiji.com — Farewell Dolly Parton, almost 20 million streams on Spotify: the highest of her career
    confidence 100%

  5. Moderna and Merck mRNA Cancer Vaccine Cuts Melanoma Recurrence by Half

    Moderna and Merck announced on August 19 that their personalized mRNA vaccine, intismeran autogene, reduced the risk of melanoma recurrence by roughly half in a Phase 3 trial of 1,137 patients. While the news initially drove Moderna shares to more than double, the stock fell 5.13% on August 24 as investors engaged in profit-taking and valuation resets. Analysts have maintained price targets below the stock's temporary peak despite the clinical success. The therapy represents the first positive Phase 3 result for a personalized neoantigen mRNA cancer vaccine.

    Why it matters

    The companies spent a decade overcoming logistical hurdles and pandemic-era obstacles to develop the treatment. This success validates the use of mRNA for individualized oncology treatments beyond infectious diseases. It also creates a positive outlook for other firms in the cancer vaccine sector.

    What is confirmed

    • Moderna and Merck announced on August 19 that intismeran autogene reduced melanoma recurrence risk by roughly half in 1,137 patients.
    • Moderna stock decreased by 5.13% on August 24 following an initial surge.
    • The development of the vaccine took a decade to overcome logistical and pandemic-era challenges.

    What to watch next

    • Regulatory filing dates for intismeran autogene
    • Analyst revisions to Moderna price targets
    • Expansion of trials to other cancer types
    Sources used for this update (5)
    1. en.protothema.gr — Mitsotakis’s order to “round up the ripe ones living off public money,” the Thessaloniki Fair, Tsipras and Samaras, the Spetses tip-offs, and is George Papandreou’s son ...
    2. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
    3. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    4. www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Down by 5.13% on Aug 24: A Full Analysis
    5. www.techtimes.com — Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half
    confidence 90%

  6. Moderna and Merck Report Positive Phase III Results for Melanoma Vaccine

    Moderna shares more than doubled following the announcement of positive Phase III trial results for intismeran, an mRNA-based individualized neoantigen therapy developed with Merck. The trial involved more than 1,000 patients and demonstrated that the vaccine helped prevent the return and spread of melanoma. The news also triggered stock surges for several sequencing companies. This development marks the first-ever positive Phase III results for an mRNA cancer vaccine, potentially opening the door for a wider range of oncology treatments.

    Why it matters

    Melanoma is the deadliest form of skin cancer. The vaccine uses personalized mRNA technology to target specific neoantigens in a patient's tumor. This approach differs from traditional treatments by tailoring the therapy to the individual's cancer profile.

    What is confirmed

    • Moderna shares more than doubled following the success of an mRNA cancer vaccine.
    • The vaccine, known as intismeran, is designed to treat melanoma.
    • Moderna and Merck reported the first-ever positive Phase III results for an mRNA-based cancer vaccine.

    Still unconfirmed

    • The vaccine helped prevent the return and spread of melanoma in a trial of more than 1,000 patients.
    • Shares of several sequencing companies surged following the announcement.

    What to watch next

    • Regulatory approval filings for intismeran
    • Expansion of mRNA vaccine trials to other cancer types
    Sources used for this update (4)
    1. www.livemint.com — It now seems possible to vaccinate against cancer
    2. omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
    3. www.genengnews.com — StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
    4. www.theglobeandmail.com — Why Tempus AI Skyrocketed This Week
    confidence 90%

  7. Moderna Shares Soar on mRNA Cancer Vaccine Success

    Moderna's shares surged after its personalized mRNA cancer vaccine, developed with Merck, showed promise in a late-stage Phase III trial for melanoma. The vaccine aims to treat the deadliest form of skin cancer and could lead to broader mRNA-based oncology treatments. Both companies are preparing for a potential market debut of the therapy.

    Why it matters

    The success of the mRNA cancer vaccine could revolutionize cancer treatment and expand the use of mRNA technology in oncology. Moderna's stock has more than doubled, causing an estimated $5 billion loss for short sellers. The vaccine's potential market debut could significantly impact the pharmaceutical and biotech industries.

    What is confirmed

    • Moderna's shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma.
    • The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved by the FDA.
    • If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.

    Still unconfirmed

    • The vaccine could change America in 7 surprising ways.

    What to watch next

    • FDA approval of the mRNA cancer vaccine
    • Market debut of the therapy
    • Results of ongoing studies in other cancers
    Sources used for this update (7)
    1. www.aol.com — Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
    2. en.sedaily.com — SK hynix to Buy Back, Cancel 40 Trillion Won in Shares; KOSPI Retakes 6,800
    3. en.sedaily.com — Korea to Build 2 More Chip Fabs in Honam, Adding to 6-Plus Plan by 2040
    4. www.cheddar.com — Big Business This Week: Bond Market Turmoil and The Broader Economy
    5. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    6. www.newsweek.com — Moderna’s Cancer Vaccine Could Change America in 7 Surprising Ways
    7. www.edaily.co.kr — Samyang Biopharm Hits Limit-Up as Moderna-MSD Cancer Vaccine Data Spark mRNA Rally [K-Bio Pulse]
    confidence 85%

  8. Moderna Shares Surge Following Positive mRNA Cancer Vaccine Trial Results

    Moderna shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma. Market reactions varied by source, with reports of stock increases ranging from 90% to 177%, causing an estimated $5 billion loss for short sellers. The vaccine aims to treat the deadliest form of skin cancer and could lead to a broader wave of mRNA-based oncology treatments. Both companies are now preparing for a potential market debut of the therapy.

    Why it matters

    This development marks a shift for Moderna from COVID-19 vaccines toward personalized cancer treatment. The partnership with Merck (MSD) focuses on using mRNA technology to trigger specific immune responses against tumors. Success in melanoma trials serves as a proof of concept for applying similar technology to other cancer types.

    What is confirmed

    • Moderna and Merck developed an mRNA cancer vaccine that showed promise in a late-stage trial.
    • The vaccine is designed to treat melanoma.
    • Moderna stock experienced a significant price increase following the trial results.
    • The vaccine uses personalized mRNA technology.

    Still unconfirmed

    • Moderna shares doubled.

    What to watch next

    • Regulatory filing and approval dates for the melanoma vaccine
    • Expansion of Phase III trials to other cancer types
    • Official revenue projections for the vaccine market debut
    Sources used for this update (10)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. WSJ — Moderna Shares Double on Success of mRNA Cancer Vaccine
    3. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
    4. Clinical Trials Arena — MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
    5. KOMO — 'Another weapon' against cancer: Personalized mRNA vaccine shows promising results
    6. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    7. CBS News — Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
    8. Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
    9. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    10. STAT — One of the most consequential year for cancer treatment, ever
    confidence 90%